-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption
Insulin resistance is a major component of the metabolic syndrome, an important feature of T2D and obesity, and a key causative factor in NASH
nonalcoholic fatty liver
These insights have led to the search for new potential treatments as our understanding of the pathophysiology of NASH continues to grow
Objective: To review the research on GLP-1RAs related to NASH treatment
Methods: PubMed was searched and the results were sorted
Results: Large trials using GLP-1RAs in T2D demonstrated highly effective glucose lowering, weight loss, and, in some cases, reductions in cardiovascular events and improvements in hepatic transaminases
Cardiovascular Event Statistics Pancreatic Cancer
Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)
Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular risk
Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular riskConclusions: These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials
These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials
Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Leave a comment here